NCT03711604View on ClinicalTrials.gov

Compassionate Use Study of Tenalisib (RP6530)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

March 25, 2023

Study Completion Date

March 25, 2023

Conditions
Hematological Malignancies
Interventions
DRUG

Tenalisib

BID Orally

Trial Locations (7)

44195

Cleveland Clinic Taussig Cancer Institute, Cleveland

77030

The University of Texas MD Anderson Cancer Center, Houston

80045

Division of Hematology, University of Colorado,, Denver

94143

University of California, Hellen Diller Family Comprehensive Cancer Center, San Francisco

Unknown

Ltd. M.Zodelava Hematology Centre, Tbilisi

Medivest - Institute of Hematology and Transfusiology, Tbilisi

41-503

Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J., Chorzów

All Listed Sponsors
lead

Rhizen Pharmaceuticals SA

INDUSTRY

NCT03711604 - Compassionate Use Study of Tenalisib (RP6530) | Biotech Hunter | Biotech Hunter